# Structure Therapeutics Inc. American (GPCR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $47.34, market value $3.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Structure Therapeutics Inc. American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -6.7%** (5-yr avg -2.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -9.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -2.6%**. Earnings per share fell 2.6%.

## Financial health
- **Current ratio: 24.81** (quick 24.81). Current assets cover the next year's liabilities 24.81 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Structure Therapeutics Inc. American does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (15 analysts). 15 analysts cover Structure Therapeutics Inc. American; the consensus is strong_buy, with an average price target of $104.77 (+121% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 139.6%** (YTD -31.9%, 3-mo 26.0%). The shares are up 139.6% over twelve months including dividends.
- **From 52-week high: -50.1%** (136.2% above the low). Trading 50% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 42**. An RSI of 42 is neutral.
- **Beta (1 yr): 0.85** (volatility 119%). Beta of 0.85 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GPCR · Page: https://foliofundamentals.com/stocks/gpcr

Not investment advice.